TrialPloS one2018

Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.

Anita J Brogan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.